TNFRSF9 and neoplasm: Ho et al reported a new class of CD137 agonist monoclonal antibody with strong anti-tumor potency without significant transaminitis in vivo, which showed crosslinking-dependent T cell co-stimulation activity in vitro (Ho et al., 2020).